Form 4: Dolby SVP John Couling Executes Stock Transactions
Statement of Changes in Beneficial Ownership
Dolby Laboratories SVP John Couling exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- John D. Couling, SVP of Entertainment at Dolby Laboratories, Inc., reported multiple transactions involving Class A Common Stock.
- On May 4, 2026, 4,688 shares were sold at an average price of $58.465.
- On May 5, 2026, 7,666 stock options were exercised at a strike price of $45.50.
- Following the exercise, 7,666 shares were sold in two tranches at weighted average prices of $57.4708 and $58.3354.
- All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 3, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine insider activity conducted under a pre-planned 10b5-1 arrangement.
Positives
- The executive maintains a significant remaining beneficial ownership of 118,353 shares.
- Transactions were executed under a pre-established 10b5-1 plan, indicating systematic rather than reactive selling.
Negatives
- The transactions represent a net reduction in the executive's direct shareholdings.
Risks
- Future share price volatility could impact the value of the remaining 55,114 unvested restricted stock units.
- Reliance on 10b5-1 plans does not eliminate market risk for the executive's remaining equity position.
Future Outlook
No specific forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard corporate practice for executives managing personal liquidity and tax obligations, and typically does not signal a change in company outlook.
Comparison to Industry Standards
- The use of 10b5-1 plans is the industry standard for senior executives to avoid potential conflicts of interest regarding material non-public information.
Stakeholder Impact
- Minimal impact expected as the transactions were pre-planned and represent a small portion of the executive's total holdings.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 2026-02-03 | Adoption date of the 10b5-1 trading plan. |
| 2026-05-04 | Date of initial reported stock sale. |
| 2026-05-05 | Date of option exercise and subsequent share sales. |
| 2026-05-06 | Date of filing signature. |
Keywords
Dolby Laboratories, DLB, Insider Trading, Form 4, Stock Options, 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.